Epirubicin and Secondary Leukemia

In this article, we will discuss Epirubicin and Secondary Leukemia. So, let’s get started.

Epirubicin and Secondary Leukemia

The occurrence of secondary acute myelogenous leukemia, with or without a preleukemic phase, has been reported in patients treated with anthracyclines. Secondary leukemia is more common when such drugs are given in combination with DNA-damaging antineoplastic agents,
when patients have been heavily pretreated with cytotoxic drugs, or when doses of the anthracyclines have been escalated. These leukemias can have a short 1- to 3-year latency period.

Epirubicin is mutagenic, clastogenic, and carcinogenic in animals.

Leave a Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.